Press release
Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)
Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.
The data seems impressive - an extraordinary 78% of patients treated with PL8177 achieved clinical response compared to just 33% for placebo, with statistical significance (p
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) here
News-ID: 3947959 • Views: …
More Releases from ABNewswire
Best AI Headshot Generator for 2026: How to Choose the Right Tool
A practical buyer's guide to choosing an AI headshot generator in 2026. Compares Magic Hour, Nano Banana (Gemini), HeadshotPro, and Canva across image realism, consistency, speed, reliability, restrictions, and cost clarity, with "best for" recommendations across common workflows.
AI headshot generators vary widely in what they optimize for. Some focus on photorealism and facial accuracy, others prioritize speed and ease of use, while some are designed for teams and brand consistency.…
$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
Small-cap stocks trading near the $5 level are back on investor watchlists as volatility and headline-driven momentum return to the market. ENDRA Life Sciences (NASDAQ: NDRA), ImmunityBio (NASDAQ: IBRX), Movano Inc. (NASDAQ: MOVE), and Rivalry Corp. (TSXV: RVLY) are all seeing renewed interest, driven by a mix of clinical progress, revenue developments, compliance milestones, and sector-specific trends.
ENDRA Life Sciences (NASDAQ: NDRA) is a medical technology company developing advanced ultrasound solutions…
$2 Stocks: DRCT, RDZN, KUST, SNYR, TOON Gaining Attention Watch Now!
Lower-priced equities trading around the $2 level are drawing renewed interest as investors search for volatility and near-term catalysts. Direct Digital Holdings (NASDAQ: DRCT), Roadzen Inc. (NASDAQ: RDZN), Kustom Entertainment (NASDAQ: KUST), Synergy CHC Corp. (NASDAQ: SNYR) and Kartoon Studios (NYSE: TOON) are all seeing increased attention tied to corporate actions, strategic shifts, and growth initiatives that could influence performance into 2026.
Direct Digital Holdings (NASDAQ: DRCT) has continued to attract…
Chronic Urticaria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the …
DelveInsight's "Chronic Urticaria Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dive into DelveInsight's comprehensive report…
More Releases for Palatin
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), Del …
The Key Moderate Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Moderate Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate Dry Eye pipeline products will significantly revolutionize the Moderate Dry Eye market dynamics.
DelveInsight's "Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Mild Dry Eye Market Growth Projections 2023-2032: DelveInsight Analysis | Palati …
The Key Mild Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Mild Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Dry Eye pipeline products will significantly revolutionize the Mild Dry Eye market dynamics.
DelveInsight's "Mild Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Pal …
The Key Dry Eye Disease Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding…
Dry Eye Disease Market to Expand Significantly by 2034, States DelveInsight Repo …
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye…
Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Resu …
Palatin Technologies (NYSE: PTN)* and their latest developments: Palatin's Oral MC4R Agonist Gets FDA Orphan Drug Status; Phase 2 Results in Drug Targeting $44 Billion Obesity Market Expected Any Day According to the Company, alongside results from ulcerative colitis trial; Only Oral Option in Market Currently Dominated by Injections Uniquely Positioning Palatin
In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan…
Dry Eye Disease Market to Show Incremental Growth, asserts DelveInsight | Promin …
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Eye Disease market report provides current treatment practices, emerging drugs, Dry Eye Disease market share of the individual therapies, current and forecasted…
